Merck KGaA reported 5.8% organic revenue growth during the third quarter to EUR 5.6 billion, which exceeded Vara-compiled consensus by 3%. Merck raised full-year EPS guidance by 3% at the midpoint. Shares traded 2% lower intraday on Nov. 12.
Merck’s life science segment is strategically positioned to capitalize on robust industry growth, driven by pharmaceutical companies’ increased R&D investments.
Merck’s healthcare segment faces significant sales declines due to patent expirations, lack of patent protection, and advancements in biologics manufacturing.
Metric | MRK | TMO | BIIB |
|---|---|---|---|
Price/Earnings (Normalized) | 20.88 | 28.33 | 21.51 |
Price/Book Value | 2.08 | 4.74 | 1.98 |
Price/Sales | 3.03 | 5.52 | 3.66 |
Price/Cash Flow | 13.64 | 25.11 | 12.51 |
Metric | MRK | TMO | BIIB |
|---|---|---|---|
Quick Ratio | 1.02 | 1.23 | 0.95 |
Current Ratio | 1.69 | 1.81 | 1.95 |
Interest Coverage | 6.10 | 5.52 | 2.10 |
Metric | MRK | TMO | BIIB |
|---|---|---|---|
Return on Assets (Normalized) | 4.06% | 8.32% | 5.75% |
Return on Equity (Normalized) | 7.14% | 17.48% | 9.42% |
Return on Invested Capital (Normalized) | 5.67% | 10.45% | 7.39% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|bd%C%g% | LOCK|mcC#p | $72B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|@r#^Js% | LOCK|MlN^ | $51B | |||
| Haleon PLC ADR HLN | LOCK|R!@>$J | LOCK|Cv> | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|Dt$Q%T$X | LOCK|&@ | $34B | |||
| Viatris Inc VTRS | LOCK|<TD>h# | LOCK|H# | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|S@Q | LOCK|J? | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|$ZG^H& | LOCK|n^ | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|^JTT&>> | LOCK|L$ | $5B | |||
| Perrigo Co PLC PRGO | LOCK|JxR<%?$ | LOCK|$! | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|@J@<^% | LOCK|@H@% | $2B |
United States